Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

References

• Bainbridge JR, Corboy JR. Multiple sclerosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey ML, editors. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill Companies, Inc.; 2008.
   Google Scholar
• Barbin L, Rousseau C, Jousset N, et al. Comparative efficacy of fingolimod vs natalizumab: a french multicenter observational study. Neurology. 2016;86(8):771–778. doi: 10.1212/WNL.0000000000002395.
   PubMed Web of Science ®Google Scholar
• Baroncini D, Ghezzi A, Annovazzi PO, et al. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. Mult Scler. 2016;22(10):1315–1326. doi: 10.1177/1352458516650736.
   PubMed Web of Science ®Google Scholar
• Bebo B, Cintina I, LaRocca N, et al. The economic burden of multiple sclerosis in the United States: estimate of direct and indirect costs. Neurology. 2022;98(18):e1810–e1817. doi: 10.1212/WNL.0000000000200150.
   PubMed Web of Science ®Google Scholar
• Biogen Idec UK. Natalizumab (tysabri) for the treatment of adults with highly active relapsing remitting multiple sclerosis. Single Technology Appraisal (STA) Submission to the National Institute for Health and Clinical Excellence. NICE Manufacturer’s Submission. 2007.
   Google Scholar
• Bozkaya D, Livingston T, Migliaccio-Walle K, et al. The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis. J Med Econ. 2017;20(3):297–302. doi: 10.1080/13696998.2016.1258366.
   PubMed Web of Science ®Google Scholar
• Braune S, Lang M, Bergmann A. Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. J Neurol. 2016;263(2):327–333. doi: 10.1007/s00415-015-7970-6.
   PubMed Web of Science ®Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32(5):722–732. doi: 10.1177/0272989X12458348.
   PubMed Web of Science ®Google Scholar
• British National Formulary. Medicines complete. 2021 [cited 2021 Nov 2]. Available from: https://www.medicinescomplete.com/mc/bnf/current/.
   Google Scholar
• Butzkueven H, Chapman J, Cristiano E, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12(6):769–774. doi: 10.1177/1352458506070775.
   PubMedGoogle Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–556. doi: 10.1016/S1474-4422(14)70049-3.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi: 10.1056/NEJMoa0907839.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain. 2006;129(Pt 3):606–616. doi: 10.1093/brain/awl007.
   PubMed Web of Science ®Google Scholar
• Craig BA, Sendi PP. Estimation of the transition matrix of a discrete-time markov chain. Health Econ. 2002;11(1):33–42. doi: 10.1002/hec.654.
   PubMed Web of Science ®Google Scholar
• Curtis L, Burns A. Unit costs of health and social care 2020. Personal Social Services Research Unit; 2020.
   Google Scholar
• Electronic Medicines Compendium. Last medicine updates. 2022 [cited 2022 August 11]. Available from: https://www.medicines.org.uk/emc/.
   Google Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. March 31, 2015; [cited 2019, March 30] Available from: https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-multiple-sclerosis.
   Google Scholar
• European Medicines Agency. Tysabri product information. June 8, 2022; [cited 2023, January 12]. Available from: https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_en.pdf.
   Google Scholar
• Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics. 2008;26(7):617–627. doi: 10.2165/00019053-200826070-00008.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Lang S, Wolff R, et al. A systematic review and mixed treatment comparison of pharmaceutical interventions for multiple sclerosis. Neurol Ther. 2020;9(2):359–374. doi: 10.1007/s40120-020-00212-5.
   PubMed Web of Science ®Google Scholar
• Guo S, Pelligra C, Saint-Laurent Thibault C, et al. Cost-effectiveness analyses in multiple sclerosis: a review of modelling approaches. Pharmacoeconomics. 2014;32(6):559–572. doi: 10.1007/s40273-014-0150-1.
   PubMed Web of Science ®Google Scholar
• He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307–316. doi: 10.1016/S1474-4422(20)30067-3.
   PubMed Web of Science ®Google Scholar
• He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol. 2015;72(4):405–413. doi: 10.1001/jamaneurol.2014.4147.
   PubMed Web of Science ®Google Scholar
• Hoepner R, Kolb EM, Dahlhaus S, et al. Predictors of severity and functional outcome in natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2017;23(6):830–835. doi: 10.1177/1352458516667241.
   PubMed Web of Science ®Google Scholar
• Hogervorst MA, Pontén J, Vreman RA, et al. Real world data in health technology assessment of complex health technologies. Front Pharmacol. 2022;13:837302. doi: 10.3389/fphar.2022.837302.
   PubMed Web of Science ®Google Scholar
• Jalkh G, Abi Nahed R, Macaron G, et al. Safety of newer disease modifying therapies in multiple sclerosis. Vaccines (Basel). 2020;9(1):12. doi: 10.3390/vaccines9010012.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Horakova D, Spelman T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015;77(3):425–435. doi: 10.1002/ana.24339.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi: 10.1056/NEJMoa0909494.
   PubMed Web of Science ®Google Scholar
• Kingwell E, van der Kop M, Zhao Y, et al. Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada. J Neurol Neurosurg Psychiatry. 2012;83(1):61–66. doi: 10.1136/jnnp-2011-300616.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77(8):918–926. doi: 10.1136/jnnp.2006.090365.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–1136. doi: 10.1177/1352458517694432.
   PubMed Web of Science ®Google Scholar
• Lasalvia P, Hernández F, Castañeda-Cardona C, et al. Cost-effectiveness of natalizumab compared with fingolimod for relapsing-remitting multiple sclerosis treatment in Colombia. Value Health Reg Issues. 2020;23:13–18. doi: 10.1016/j.vhri.2019.08.481.
   PubMedGoogle Scholar
• Lorscheider J, Benkert P, Lienert C, et al. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis. Mult Scler. 2018;24(6):777–785. doi: 10.1177/1352458518768433.
   PubMed Web of Science ®Google Scholar
• Lorscheider J, Benkert P, Lienert C, et al. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis. J Neurol. 2021;268(3):941–949. doi: 10.1007/s00415-020-10226-6.
   PubMed Web of Science ®Google Scholar
• Makady A, van Veelen A, Jonsson P, et al. Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics. 2018;36(3):359–368. doi: 10.1007/s40273-017-0596-z.
   PubMed Web of Science ®Google Scholar
• Michels RE, de Fransesco M, Mahajan K, et al. Cost effectiveness of cladribine tablets for the treatment of relapsing-remitting multiple sclerosis in The Netherlands. Appl Health Econ Health Policy. 2019;17(6):857–873. doi: 10.1007/s40258-019-00500-8.
   PubMed Web of Science ®Google Scholar
• MidMeds. Siemens Multistix 10 SG Professional Urine Reagent Test Strips. December 2, 2021. Available from: http://www.midmeds.co.uk/siemens-bayer-multistix-p-234.html.
   Google Scholar
• Montgomery SM, Maruszczak MJ, Slater D, et al. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. J Med Econ. 2017;20(5):474–482. doi: 10.1080/13696998.2016.1276070.
   PubMed Web of Science ®Google Scholar
• National Health Service. 2019/20 National cost collection data publication. 2019-20; [cited 2021, November 2]. Available from: https://www.england.nhs.uk/publication/2019-20-national-cost-collection-data-publication/.
   Google Scholar
• National Institute for Health and Care Excellence. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis. April 2012. Technology Appraisal No. 254.
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2022; [cited 2023, September 18]. Available from: https://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation.
   Google Scholar
• National Institute for Health and Care Excellence. List of technologies with approved patient access schemes. 2022; [cited 2022, February 16]. Available from: https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit#list-of-arrangements.
   Google Scholar
• National Institute for Health and Care Excellence. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis. August 2007. Technology Appraisal No. 127.
   Google Scholar
• Nottingham University Hospitals. High cost tests referred to other labs. [cited 2017, February 9]. Available from: https://www.nuh.nhs.uk/staff-area/microbiology/turnaround-times/high-cost-referred-tests/.
   Google Scholar
• O'Day K, Meyer K, Miller RM, et al. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. J Med Econ. 2011;14(5):617–627. doi: 10.3111/13696998.2011.602444.
   PubMedGoogle Scholar
• O'Day K, Meyer K, Stafkey-Mailey D, et al. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. J Med Econ. 2015;18(4):295–302. doi: 10.3111/13696998.2014.991786.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Consumer Price Index. 2021. [cited 2021, December 1]. Available from: https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/d7bz/mm23.
   Google Scholar
• Office for National Statistics. National life tables, United Kingdom, 2014-2016. 2018; [cited 2018, January 30]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables.
   Google Scholar
• Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved markov model. BMJ Open. 2014;4(1):e004073. doi: 10.1136/bmjopen-2013-004073.
   PubMed Web of Science ®Google Scholar
• Pokorski RJ. Long-term survival experience of patients with multiple sclerosis. J Insur Med. 1997;29(2):101–106.
   PubMedGoogle Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910. doi: 10.1056/NEJMoa044397.
   PubMed Web of Science ®Google Scholar
• Prosperini L, Saccà F, Cordioli C, et al. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naive patients with multiple sclerosis. J Neurol. 2017;264(2):284–294. doi: 10.1007/s00415-016-8343-5.
   PubMed Web of Science ®Google Scholar
• Rassen JA, Shelat AA, Franklin JM, et al. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013;24(3):401–409. doi: 10.1097/EDE.0b013e318289dedf.
   PubMed Web of Science ®Google Scholar
• Roos I, Diouf I, Sharmin S, et al. Comparative effectiveness in multiple sclerosis: a methodological comparison. Mult Scler. 2023;29(3):326–332. doi: 10.1177/13524585231151394.
   PubMed Web of Science ®Google Scholar
• Ryerson LZ, Foley J, Chang I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452–e1462. doi: 10.1212/WNL.0000000000008243.
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt 7):1914–1929. doi: 10.1093/brain/awq118.
   PubMed Web of Science ®Google Scholar
• Schumacher GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122(1):552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x.
   PubMedGoogle Scholar
• Simpson A, Mowry EM, Newsome SD. Early aggressive treatment approaches for multiple sclerosis. Curr Treat Options Neurol. 2021;23(7):19. doi: 10.1007/s11940-021-00677-1.
   PubMed Web of Science ®Google Scholar
• Spelman T, Herring WL, Zhang Y, et al. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom. Pharmacoeconomics. 2022;40(3):323–339. doi: 10.1007/s40273-021-01106-6.
   PubMed Web of Science ®Google Scholar
• Spelman T, Horakova D, Ozakbas S, et al. Switching to natalizumab or fingolimod in multiple sclerosis: comparative effectiveness and effect of pre-switch disease activity. Mult Scler Relat Disord. 2023;70:104477. doi: 10.1016/j.msard.2022.104477.
   PubMed Web of Science ®Google Scholar
• Spelman T, Kalincik T, Zhang A, et al. Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol. 2015;2(4):373–387. doi: 10.1002/acn3.180.
   PubMed Web of Science ®Google Scholar
• Thompson A, Kobelt G, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for the United Kingdom. Mult Scler. 2017;23(2_suppl):204–216. doi: 10.1177/1352458517708687.
   PubMed Web of Science ®Google Scholar
• Tramacere I, Del Giovane C, Filippini G. Association of immunotherapies with outcomes in relapsing-remitting multiple sclerosis. JAMA. 2016;315(4):409–410. doi: 10.1001/jama.2015.18984.
   PubMed Web of Science ®Google Scholar
• Trojano M, Tintore M, Montalban X, et al. Treatment decisions in multiple sclerosis—insights from real-world observational studies. Nat Rev Neurol. 2017;13(2):105–118. doi: 10.1038/nrneurol.2016.188.
   PubMed Web of Science ®Google Scholar
• Vargas WS, Perumal JS. Fingolimod and cardiac risk: latest findings and clinical implications. Ther Adv Drug Saf. 2013;4(3):119–124. doi: 10.1177/2042098613481023.
   PubMedGoogle Scholar
• Vollmer B, Ontaneda D, Harris H, et al. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci. 2019;407:116498. doi: 10.1016/j.jns.2019.116498.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ. 2016;354:i3518. doi: 10.1136/bmj.i3518.
   PubMed Web of Science ®Google Scholar